126 related articles for article (PubMed ID: 31027993)
1. Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient.
Schulz M; Papp CP; Bock CT; Hofmann J; Gerlach UA; Maurer MM; Eurich D; Mueller T
J Hepatol; 2019 Jul; 71(1):225-227. PubMed ID: 31027993
[No Abstract] [Full Text] [Related]
2. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
van der Valk M; Zaaijer HL; Kater AP; Schinkel J
J Hepatol; 2017 Jan; 66(1):242-243. PubMed ID: 27702641
[No Abstract] [Full Text] [Related]
3. Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
Todesco E; Demeret S; Calin R; Roque-Afonso AM; Thibault V; Mallet V; Akhavan S; Jaspard M; Peytavin G; Poynard T; Katlama C; Pourcher V
AIDS; 2017 Jun; 31(9):1346-1348. PubMed ID: 28492398
[No Abstract] [Full Text] [Related]
4. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis E infection in an immunosuppressed, solid organ transplant patient.
Forgan-Smith KR; Macdonald G
Intern Med J; 2019 Oct; 49(10):1335-1336. PubMed ID: 31602774
[No Abstract] [Full Text] [Related]
6. Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin.
Biliotti E; Franchi C; Spaziante M; Garbuglia AR; Volpicelli L; Palazzo D; De Angelis M; Esvan R; Taliani G
Infection; 2018 Oct; 46(5):725-727. PubMed ID: 29946850
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
8. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.
Debing Y; Gisa A; Dallmeier K; Pischke S; Bremer B; Manns M; Wedemeyer H; Suneetha PV; Neyts J
Gastroenterology; 2014 Nov; 147(5):1008-11.e7; quiz e15-6. PubMed ID: 25181691
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
[TBL] [Abstract][Full Text] [Related]
10. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
Welker MW; Luhne S; Lange CM; Vermehren J; Farnik H; Herrmann E; Welzel T; Zeuzem S; Sarrazin C
J Hepatol; 2016 Apr; 64(4):790-9. PubMed ID: 26658684
[TBL] [Abstract][Full Text] [Related]
11. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study.
Péron JM; Abravanel F; Guillaume M; Gérolami R; Nana J; Anty R; Pariente A; Renou C; Bureau C; Robic MA; Alric L; Vinel JP; Izopet J; Kamar N
Liver Int; 2016 Mar; 36(3):328-33. PubMed ID: 26179015
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Shah SR; Chowdhury A; Mehta R; Kapoor D; Duseja A; Koshy A; Shukla A; Sood A; Madan K; Sud R; Nijhawan S; Pawan R; Prasad M; Kersey K; Jiang D; Svarovskaia E; Doehle B; Kanwar B; Subramanian M; Acharya SK; Sarin S
J Viral Hepat; 2017 May; 24(5):371-379. PubMed ID: 27933698
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
Elbaz T; Abdo M; Omar H; Hassan EA; Zaghloul AM; Abdel-Samiee M; Moustafa A; Qawzae A; Gamil M; Esmat G
J Med Virol; 2019 Feb; 91(2):272-277. PubMed ID: 30138531
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients.
Cordts SE; Schneble L; Schnitzler P; Wenzel JJ; Vinke T; Rieger S; Fichtner A; Tönshoff B; Höcker B
Pediatr Nephrol; 2018 Jul; 33(7):1215-1225. PubMed ID: 29500631
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin long-term treatment for chronic hepatitis E virus infection in a liver transplant recipient.
Casper M; Reichert MC; Rissland J; Grünhage F; Lammert F
Dig Liver Dis; 2020 Aug; 52(8):926-927. PubMed ID: 32553699
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
[TBL] [Abstract][Full Text] [Related]
20. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT
J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
